Opicapone original manufacturer information and drug background introduction

Opicapone (Opicapone) is a new type of catechol-O-methyltransferase (COMT) inhibitor, mainly used for adjuvant treatment of patients with Parkinson's disease. It inhibits the activity of peripheral COMT enzymes and prolongs the action time of Levodopa (Levodopa) in the body, thereby helping to improve the "switching phenomenon" and drug effect fluctuations that occur in patients with Parkinson's disease during the use of Levodopa. As a drug with a clear mechanism of action and precise efficacy, the clinical application value of Opicapone has been gradually recognized around the world.

The original manufacturer of Opicapone is Portugal BIAL Pharmaceutical Company, which is a pharmaceutical company with a high reputation in Europe. BIALThe company has long been focused on research in the field of central nervous system diseases, and Opicapone is an important result of its research and development of drugs for the treatment of Parkinson's disease. In 2016, Opicapone was the first to be approved for marketing in Europe, with the trade name Ongentys, and then gradually entered the market in the United States and other countries. The successful launch of the drug not only provides a new treatment option for patients with Parkinson's disease, but also marks an important breakthrough for BIAL in the international pharmaceutical field.

In addition toBIAL, other partners are also involved in the global commercial promotion of Opicapone. Especially in the US market, BIAL cooperates with Neurocrine Biosciences , which is responsible for the promotion and sales in the United States. This cooperation model enables Opicapone to be accepted by doctors and patients faster in different regions, expanding the accessibility and market coverage of the drug. At the same time, as an innovative auxiliary drug, Opicapone has also been recommended by many Parkinson's disease academic organizations and clinical guidelines.

In terms of drug background, Opicapone, as a once-daily oral COMT inhibitor, has the characteristics of a single dose, high compliance, and relatively mild side effects, which gives it more clinical advantages than traditional Entacapone (Entacapone). It can significantly reduce the "off period" caused by excessive levodopa metabolism in patients, improve motor symptoms, and improve quality of life. Overall, the R&D background, manufacturer strength and clinical application value of Opicapone make it an important new option in the treatment system for Parkinson's disease.

Reference link:https://www.drugs.com